All In Biotech

Drug Trial Radar · NCT01703533

A Safety Study of NNZ-2566 in Patients With Rett Syndrome

A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation Study of NNZ-2566 in Rett Syndrome

Last checked: Nov 19, 2026Latest source record: Feb 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

67

Actual

Start

Mar 2013

Primary completion

Sep 2014

Study completion Sep 2014

Sponsor

Lead sponsor
Neuren Pharmaceuticals LimitedIndustry
Sponsor type
Industry
Collaborators
Baylor College of Medicine; International Rett Syndrome Foundation
First posted
Oct 10, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 16 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of Rett Syndrome in adolescent and adult females.

Conditions

  • Rett Syndrome

Interventions

  • NNZ-2566Drug

    Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.

  • PlaceboDrug

    Strawberry flavored solution and Water for Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventsTime frame: Through to Day 40

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama

    Birmingham, Alabama

  • Gillette Children's Specialty Healthcare

    Saint Paul, Minnesota

  • Baylor School of Medicine

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.